|
| Status |
Public on Dec 20, 2021 |
| Title |
day 8 anti PD-1 mouse 3 tumor |
| Sample type |
RNA |
| |
|
| Source name |
tumor
|
| Organism |
Mus musculus |
| Characteristics |
strain: C57BL/6J
tissue: CT26 tumor
treatment: anti-PD-1
time point: day 8
|
| Treatment protocol |
FFPE blocks prepared.
|
| Growth protocol |
The adherent colorectal carcinoma cell line CT26 (cat. # CRL-2638, ATCC, Manassas, VA) and mammary gland adenocarcinoma cell line JC (cat. # CRL-2116, ATCC, Manassas, VA) were expanded and maintained in RPMI-1640 (Roswell Park Memorial Institute medium cat. # SH30021.02 GE Healthcare Life Sciences) supplemented with 10% FBS (cat. # F442-500 Sigma-Aldrich).
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA processed from formalin fixed paraffin embedded (FFPE) blocks as per NanoStringTM protocols.
|
| Label |
n/a
|
| Label protocol |
Labeled as to group, mouse number and tissue.
|
| |
|
| Hybridization protocol |
Samples processed as per NanoStringTM protocols.
|
| Scan protocol |
NanoStringTM nCounter.
|
| Description |
group 2 8 tumor
|
| Data processing |
Normalization method NanoStringTM nSolver 4.0 advanced analysis, normalised to standards on NanoStringTM panel per their protocol.
|
| |
|
| Submission date |
Nov 22, 2021 |
| Last update date |
Dec 20, 2021 |
| Contact name |
Kyle Halliwill |
| E-mail(s) |
kyle.halliwill@gmail.com
|
| Organization name |
Abbvie Inc
|
| Street address |
1500 Seaport Blvd
|
| City |
Redwood City |
| State/province |
California |
| ZIP/Postal code |
94063 |
| Country |
USA |
| |
|
| Platform ID |
GPL30298 |
| Series (1) |
| GSE189359 |
Gene expression based outcome of CT-26 tumor in C57/BL6 mice after treatment with anti-PD-1 antibody, GITR-L, combination or Bispecific molecules |
|
